@article{ref1,
title="Reboxetine in clinic and psychiatric practice: Results of two observational studies",
journal="Psychopharmakotherapie",
year="2000",
author="Laux, G. and Schuler, P. and Bruns, S.",
volume="7",
number="4",
pages="162-167",
abstract="The specific noradrenergic antidepressant reboxetine was further characterised in two observational studies involving 5 292 patients (793 hospitalised and 4499 outpatients). The demographic data of both groups of patients were comparable. However, the hospitalised patients were very more severely affected with a total Clinical Global Impression (CGI) score of 5,1 (versus 4,6 of the outpatients). The mean dose of reboxetine was 6,3 mg/day over the observational period of about 4 weeks. The incidence of withdrawals due to adverse events was 10.5% in the hospitalised group and 7.8 % in the outpatient group. Blood pressure was not affected in the total sample. One case of suicide was observed. Suicidal tendencies according to the Montgomery-Asberg Depression Rating and Self-evaluation Depression Scales (MADRS and SDS) were relevantly decreasing over the observational period. After 4 weeks of therapy, 58,7 % of the outpatients and 59,1 % of the hospitalised patients (evaluable cases) were rated as much or very much improved in the CGI-scale impression (CGI) scale, item 2.<p /><p>Language: en</p>",
language="en",
issn="0944-6877",
doi="",
url="http://dx.doi.org/"
}